We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF
PPH

44 hedge funds and large institutions have $122M invested in VanEck Pharmaceutical ETF in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 19 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.94% less ownership

Funds ownership: 47.22% → 44.28% (-2.9%)

6% less capital invested

Capital invested by funds: $131M → $122M (-$8.35M)

10% less funds holding

Funds holding: 49 → 44 (-5)

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

68% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 19

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1.04M

Holders
44
Holders Change
-5
Holders Change %
-10.2%
% of All Funds
1.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
19
Closed
8
Calls
–
Puts
$1.04M
Net Calls
-$1.04M
Net Calls Change
-$122K

Top Buyers

Rank Fund Capital Flow
1
Janney Montgomery Scott
Janney Montgomery Scott
Pennsylvania
+$349K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$127K
3
UBS Group
UBS Group
Switzerland
+$59.4K
4
APP
Avantax Planning Partners
Iowa
+$46.7K
5
LPL Financial
LPL Financial
California
+$39.1K

Top Sellers

Rank Fund Capital Flow
1
BCI
Brinker Capital Investments
Pennsylvania
-$8.67M
2
VF
Virtu Financial
New York
-$2.02M
3
Morgan Stanley
Morgan Stanley
New York
-$1.99M
4
Citadel Advisors
Citadel Advisors
Florida
-$1.61M
5
TRCT
Tower Research Capital (TRC)
New York
-$1.45M
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$120K -$4.99K -80 -4%
AG
27
Advisor Group
Arizona
$68K -$24.9K -400 -28%
TCM
28
Tradewinds Capital Management
Washington
$64K – – –
ASN
29
Advisory Services Network
Georgia
$50K – – –
MIM
30
Macroview Investment Management
Maryland
$49K +$62 +1 +0.1%
HCM
31
Highlander Capital Management
New Jersey
$48K – – –
APP
32
Avantax Planning Partners
Iowa
$48K +$46.7K +750 New
CFGS
33
Concourse Financial Group Securities
Alabama
$32K +$31.2K +500 New
FDCDDQ
34
Federation des caisses Desjardins du Quebec
Quebec, Canada
$25.7K -$125K -2,000 -83%
WWM
35
Willingdon Wealth Management
North Carolina
$22K – – –
JCM
36
Jacobi Capital Management
Pennsylvania
$13K -$15.2K -244 -55%
William Blair & Company
37
William Blair & Company
Illinois
$13K – – –
ADL
38
Asset Dedication LLC
California
$11K – – –
IA
39
IFP Advisors
Florida
$10K – – –
CWA
40
Clarus Wealth Advisors
Arizona
$6K – – –
FANJ
41
Financial Architects (New Jersey)
New Jersey
$5K – – –
AIM
42
Anchor Investment Management
South Carolina
$3.73K – – –
BFEC
43
Benjamin F. Edwards & Company
Missouri
$1K – – –
BCI
44
Brinker Capital Investments
Pennsylvania
– -$8.67M -147,000 Closed
VF
45
Virtu Financial
New York
– -$2.02M -34,244 Closed
PVH
46
Psagot Value Holdings
Israel
– -$1M -17,000 Closed
TSS
47
Two Sigma Securities
New York
– -$264K -4,483 Closed
NL
48
NVWM LLC
Pennsylvania
– -$89K -1,502 Closed
GT
49
Glenmede Trust
Pennsylvania
– -$59K -1,000 Closed
CPA
50
Clear Perspective Advisors
Illinois
– -$18K -300 Closed
1
2
3

PPH Hedge Fund Activity: Q3 2018 in Review

44 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q3 2018, worth a combined $122M — down 6.4% from $131M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of PPH and 3 opened new positions — a net loss of 5 holders — while 19 trimmed existing stakes and 6 added.

The largest buyer was Janney Montgomery Scott, opening a new position worth an estimated $349K. The largest seller was Brinker Capital Investments, exiting entirely with an estimated $8.67M sold.

  • 44 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q3 2018, down from 49 in Q2 2018.
  • Funds reported $122M of VanEck Pharmaceutical ETF stock for Q3 2018, down 6.4% quarter-over-quarter.
  • 3 funds opened new VanEck Pharmaceutical ETF positions in Q3 2018 and 8 closed out, a net change of -5 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q3 2018 was Janney Montgomery Scott, an estimated $349K added.
  • The largest VanEck Pharmaceutical ETF seller in Q3 2018 was Brinker Capital Investments, an estimated $8.67M sold.

Based on aggregated 13F filings for Q3 2018.